Evidence map›Paper›PMID 37289979›Full record

ArticleACS chemical neuroscience2023

Disease-Modifying Effects of Vincamine Supplementation in

Francisco José Sanz, Cristina Solana-Manrique, Nuria Paricio

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS chemical neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Acteoside exerts neuroprotective effects by preventing α-synuclein aggregation and oxidative stress in models of Parkinson's disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Francisco José SanzDepartamento de Genética, Facultad de Ciencias Biológicas, Universidad de Valencia, Burjassot 46100, Spain.
Cristina Solana-ManriqueDepartamento de Genética, Facultad de Ciencias Biológicas, Universidad de Valencia, Burjassot 46100, Spain.
Nuria ParicioDepartamento de Genética, Facultad de Ciencias Biológicas, Universidad de Valencia, Burjassot 46100, Spain.ORCID 0000-0001-7193-2532
Universitat de València · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is an incurable neurodegenerative disorder caused by the selective loss of dopaminergic neurons in the

Indexed as

Drosophila ProteinsNeuroblastomaParkinson DiseaseVincamineAnimalsDietary SupplementsDrosophilaHumansNerve Tissue ProteinsOxidative StressProtein Deglycase DJ-1DJ-1beta protein, DrosophilaDrosophila ProteinsNerve Tissue ProteinsPARK7 protein, humanProtein Deglycase DJ-1VincamineDJ-1Drosophilanutraceuticalsoxidative stressParkinson’s diseasetherapeutic compoundsvincaminevoltage gated Na+ channels

Identifiers

PMID37289979
PMCPMC10288506
OpenAlexW4379930983

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.